Measurement aggregates

Turro and Yekta [142] discussed a simple method for measuring aggregation number by steady-state fluorescence. In this method, the decrease of the fluorescence intensity of a micelle-bound probe is monitored as a function of the quencher concentration and is fitted to the equation [143]... 

However, the most intuitive way of measuring aggregate formation in solution is the measurement of the light scattered by protein-tannin particles. In fact nephelometry and other light-scattering measurement techniques have been widely used to study protein-tannin interactions [33, 34, 44—49]. 

Fig. 13.8. Correlation between expression levels and the measured aggregation rates for a set of human proteins. The aggregation rates represent all the data obtained from a comprehensive search of the amyloid aggregation literature, for studies carried out at pH values between 4.0 and 8.0. The expression levels are estimated from the cellular mRNA concentration and are taken from published databases. The standard deviations of the aggregation rates are reported only in four cases, as these values are generally not available or difficult to extract from the literature. Data for two proteins not involved in any known medical conditions are included in the plot while the other points correspond to proteins that are associated with amyloid diseases. From [4]...

Frojmovic MM, Milton Xi, Duchastel A. Microscopicmeasurementsofplatelet aggregation reveal alow ADP-dependent process distinct from turbidometrically measured aggregation. JLab Oin Med 1983 101 964-976. 

Therefore, to estimate or measure aggregate exposures, relevant and reliable data are required. Further, aggregate exposure assessment methods and modeling tools are needed that more accurately reflect real-life situations (in contrast to methods and models that are based on very conservative assumptions and may lead to less realistic and sometimes gross overestimates of exposure). 

The boundary condition used for Equations 12 and 13 is that the calculated total volume of aggregates equals the measured aggregate volume. 

Haynes, R. J. (20()0). Interactions between soil organic matter status, cropping history, method of ciuantilication and sample pretreatmenl and theii- effects on measured aggregate stability. Biol. Fertil. Soils 30, 270-275. 

An additional study (12), contrasts the behavior of titanium dioxide sonicated for 10 minutes in distilled water. The particles had a hydrodynamic diameter of 20 nm. If one combines this with the BET diameter determined in dry powder at the time of density measurements, aggregation would have been expected to be minimal, less than four particles per unit diameter (12). Further studies of these fine dusts (6), ranging up to 2000 nm, were used to assess cellular response. 

Wet methods may be used in which the powder is suspended in a liquid, usually water with a surfactant to overcome flocculation of aggregates. Aggregate size can then be determined by diluting out the suspension and measuring aggregate sizes by optical microscopy. 

Use measurement aggregation. In developmental-behavioral stndies not all measures of a construct have equal sensitivity. Therefore it is important to nse converging multiple measures of the construct so a real link is not missed due to reliance on a single, less-sensitive measure. 

Proteins must be non-aggregated and monomeric, or at least not present as large heteromultimers, under conditions of NMR measurements. Aggregated proteins give increased line widths and thus reduced spectral resolution and sensitivity. Internal mobility and the presence of multiple interconverting conformations also influence resonance line width. 

Value attributes will need to be collected, measured, aggregated and converted to evaluate a value metric (Deloitte, 2012). The data that will feed into this assessment will need to go beyond purely clinical trial data. Real-world data - that is, data relevant to the drug in use, not just in trials - would apply both before the market laimch (e.g. up-to-date cost of illness data) and post-launch comparative real-world data, information on side effects and changes in effectiveness over time (Greiner, 2011). The sources of such data could transcend patients, clinicians, hospitals and social networks. The quality of the data and its format, governance and ethical considerations are likely to influence the feasibility and extent to which VBP can reflect real-world values. There may well be a need for the development of new methods which can assess value in different contexts and under different conditions, and which can incorporate trade-offs. 

---